Literature DB >> 23522897

High-risk anaemic Jehovah's Witness patients should be managed in the intensive care unit.

Andrei M Beliaev.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23522897      PMCID： PMC3729120          DOI： 10.2450/2013.0043-13

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  28 in total

1.  Mortality risk stratification in severely anaemic Jehovah's Witness patients.

Authors:  A M Beliaev; R J Marshall; W Smith; J A Windsor
Journal:  Intern Med J       Date:  2012-03       Impact factor: 2.048

2.  Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells).

Authors:  H Bao; S M Jacobs-Helber; A E Lawson; K Penta; A Wickrema; S T Sawyer
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

3.  Clinical benefits and cost-effectiveness of allogeneic red-blood-cell transfusion in severe symptomatic anaemia.

Authors:  A M Beliaev; R J Marshall; M Gordon; W Smith; J A Windsor
Journal:  Vox Sang       Date:  2011-12-13       Impact factor: 2.144

4.  Preoperative methods to improve erythropoiesis.

Authors:  A Bacuzzi; G Dionigi; G Piffaretti; M Tozzi; M Del Romano; L Guzzetti; F Paracchini; F Villa; S Cuffari
Journal:  Transplant Proc       Date:  2011 Jan-Feb       Impact factor: 1.066

Review 5.  Management of adult Jehovah's Witness patients with acute bleeding.

Authors:  Kenrick Berend; Marcel Levi
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

6.  Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials.

Authors:  Ryan Zarychanski; Alexis F Turgeon; Lauralyn McIntyre; Dean A Fergusson
Journal:  CMAJ       Date:  2007-09-05       Impact factor: 8.262

7.  Time course and etiology of death in patients with severe anemia.

Authors:  Aaron A R Tobian; Paul M Ness; Helaine Noveck; Jeffrey L Carson
Journal:  Transfusion       Date:  2009-03-23       Impact factor: 3.157

8.  Efficacy and safety of epoetin alfa in critically ill patients.

Authors:  Howard L Corwin; Andrew Gettinger; Timothy C Fabian; Addison May; Ronald G Pearl; Stephen Heard; Robert An; Peter J Bowers; Paul Burton; Mark A Klausner; Michael J Corwin
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

Review 9.  Erythropoietin in heart and vessels: focus on transcription and signalling pathways.

Authors:  Francesca Marzo; Alberto Lavorgna; Giulio Coluzzi; Eleonora Santucci; Federica Tarantino; Teresa Rio; Elena Conti; Camillo Autore; Luciano Agati; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2008-03-13       Impact factor: 2.300

Review 10.  Erythropoietin and the endothelium - a promising link?

Authors:  D Fliser; F H Bahlmann
Journal:  Eur J Clin Invest       Date:  2008-05-21       Impact factor: 4.686
View more
  3 in total

1.  Successful Treatment of Severe Anemia using Erythropoietin in a Jehovah Witness with Non-Hodgkin Lymphoma.

Authors:  Alexandra Agapidou; Sofia Vakalopoulou; Theodosia Papadopoulou; Christina Chadjiaggelidou; Vasileia Garypidou
Journal:  Hematol Rep       Date:  2014-12-04

2.  Cost-equivalence and Pluralism in Publicly-funded Health-care Systems.

Authors:  Dominic Wilkinson; Julian Savulescu
Journal:  Health Care Anal       Date:  2018-12

3.  Hemoglobin-Based Oxygen Carrier for Traumatic Hemorrhagic Shock Treatment in a Jehovah's Witness.

Authors:  Joseph A Posluszny; Lena M Napolitano
Journal:  Arch Trauma Res       Date:  2016-02-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.